Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Features
29 May 08
10 simple points to remember when writing a great CV. Your CV is the first point of contact between you and a prospective new employer. It is unlikely that the reader will know anything about you except what’s in the CV – so try to see it from their perspective.
Gwyneth Holland
29 May 08
A great summary of points to remember when writing your job application covering letter. The main purpose of a covering letter is to present your CV in support of your job application. This may be obvious, but it’s surprising how many people appear to think that a covering letter needs to be long and complicated and somehow justify its own existence..
Gwyneth Holland
21 May 08
We have an enviable position of being visited by over 150,000 people each month looking for pharmaceutical news and jobs, and we need to satisfy their desire for content.
Mike Wood
13 May 08
In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments.
Editor
09 May 08
“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
Nini Wei- Visiongain Ltd
06 May 08
The ins and outs of the daily life for Medical Sales Reps.
Philip Miles
15 Apr 08
Why do some people have allergies and some not? And why has the prevalence of allergic disorders been increasing over the past century, especially in industrialised, developed countries?
Mike Wood
11 Apr 08
Which current or future therapies will drive the sleep disorders market from 2008 to 2018?
What is the patient identification rate for each of the therapeutic areas?
What is the present state of the disease awareness?
What R&D opportunities exist for ‘new comers’?
Which key companies are involved in the market?
Justyna Drozdzal
01 Apr 08
Forget sweat patches, VPLs and spots…a new survey commissioned by Kleenex® has found that it’s blowing your nose in public that causes us the most embarrassment! The survey of hay fever sufferers reveals that most people prefer a quiet sniff over a good nose blow when out and about. However, allergy specialists warn that the more discreet option actually makes symptoms worse.
Jasmine Richards
31 Mar 08
Asthma is a significant health problem. Acording to the National Asthma Campaign, the condition continues to grow, and in the UK an estimated 8 million people are diagnosed as having asthma, with 5 million people receiving treatment. The cost of asthma to the NHS is more than £850 million a year.
Mike Wood
25 Mar 08
Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
Deborah Cockerill
12 Mar 08
Research led by the University of Warwick has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin. The same research could also open up MRSA to attack by penicillin and help create a library of designer antibiotics to use against a range of other dangerous bacteria.
Editor
11 Dec 07
Roche to announce new breast cancer data pointing to
better survival chances and potential for cure
Phase II results suggest Avastin can be used in curative setting
Anne Cameron
04 Dec 07
Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication.
Olwen Glynn Owen - Pharmiweb Field Reporter
28 Nov 07
Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you.
Colin Williams
27 Nov 07
PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here.
Editor
25 Sep 07
Two things; firstly among all of the great business concepts of the last few
decades the franchise model has always surfaced to the very top. Secondly,
over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Naseem Javed
06 Sep 07
Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP).
Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Colin Williams
30 Jul 07
BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen
25 Jul 07
Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007
second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to
$5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half.
Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7%
for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus
02 Jul 07
Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington
11 Jun 07
The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen
11 Jun 07
Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor
08 Jun 07
Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen
05 Jun 07
In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
Lhasa Limited
04 Jun 07
Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen
23 May 07
In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
Paula Mumby
22 May 07
With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
Paul Hartigan
14 May 07
Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
Naseem Javed
10 May 07
Its hard gaining entry into the pharmaceutical industry, but is it harder if you are thirty? I’m a graduate, so I can get in like a graduate, can’t I?
Toni Gardner
